• Histopathological results of radical prostatectomy specimen of men younger than 50 years of age at the time of surgery: possible implications for prostate cancer screening programs?
    • Mehring G, Tilki D, Heinzer H, Steuber T, Pose RM, Thederan I, Budäus L, Salomon G, Haese A, Michl U, Maurer T, Huland H, Graefen M, Isbarn H.
    • World J Urol. 2023 Jan 19. doi: 10.1007/s00345-023-04287-1. Epub ahead of print.
    • Prostate cancer risk, screening and management in patients with germline BRCA1/2 mutations.
    • Rajwa P, Quhal F, Pradere B, Gandaglia G, Ploussard G, Leapman MS, Gore JL, Paradysz A, Tilki D, Merseburger AS, Morgan TM, Briganti A, Palapattu GS, Shariat SF.
    • Nat Rev Urol. 2023 Jan 4. doi: 10.1038/s41585-022-00680-4. Epub ahead of print.
    • Review
    • Germline mutations in prostate cancer: a systematic review of the evidence for personalized medicine.
    • Marino F, Totaro A, Gandi C, Bientinesi R, Moretto S, Gavi F, Pierconti F, Iacovelli R, Bassi P, Sacco E.
    • Prostate Cancer Prostatic Dis. 2022 Nov 24. doi: 10.1038/s41391-022-00609-3. Epub ahead of print.
    • Review
    • Stellenwert der genetischen Testung beim Prostatakarzinom [Importance of genetic testing in prostate cancer].
    • Steinkellner L, Luger F, Loidl W.
    • Urologie. 2022 Nov 15. German. doi: 10.1007/s00120-022-01977-3. Epub ahead of print.
    • Review. [Article in German]
    • Dr. Shore on the Importance of Genetic Testing in Prostate Cancer.
    • Shore N.
    • OncLive. OncLive TV. 2022 Nov 11.
    • Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline.
    • Sessa C, Balmaña J, Bober SL, Cardoso MJ, Colombo N, Curigliano G, Domchek SM, Evans DG, Fischerova D, Harbeck N, Kuhl C, Lemley B, Levy-Lahad E, Lambertini M, Ledermann JA, Loibl S, Phillips KA, Shimon P; ESMO Guidelines Committee.
    • Ann Oncol. 2022 Oct 19:S0923-7534(22)04193-X. doi: 10.1016/j.annonc.2022.10.004. Epub ahead of print.
    • Initial outcomes and insights from a novel high-risk prostate cancer screening clinic.
    • Harper JB, Greenberg SE, Hunt TC, Cooney KA, O'Neil BB.
    • Prostate. 2022 Oct 7. doi: 10.1002/pros.24447. Epub ahead of print.
    • Controversies and Open Questions in Management of Cancer-Free Carriers of Germline Pathogenic Variants in BRCA1/BRCA2.
    • Bernstein-Molho R, Friedman E, Evron E.
    • Cancers (Basel). 2022 Sep 22;14(19):4592. doi: 10.3390/cancers14194592.
    • The role of prophylactic prostatectomy as a primary prevention strategy in high-risk germline mutation carriers.
    • Tiwari R, Clark R, Fleshner N.
    • Curr Opin Urol. 2022 Sep 1;32(5):445-450. doi: 10.1097/MOU.0000000000001019. Epub 2022 Jul 18.
    • Review
    • Novel germline mutations for active surveillance and imaging strategies in prostate cancer.
    • Mondschein R, Taylor R, Thorne H, Bolton D.
    • Curr Opin Urol. 2022 Sep 1;32(5):456-461. doi: 10.1097/MOU.0000000000001024. Epub 2022 Jul 18.
    • Review
    • Inherited risk assessment and its clinical utility for predicting prostate cancer from diagnostic prostate biopsies.
    • Xu J, Resurreccion WK, Shi Z, Wei J, Wang CH, Zheng SL, Hulick PJ, Ross AE, Pavlovich CP, Helfand BT, Isaacs WB.
    • Prostate Cancer Prostatic Dis. 2022 Sep;25(3):422-430. doi: 10.1038/s41391-021-00458-6. Epub 2022 Mar 28.
    • Review
    • Active Surveillance in Intermediate-Risk Prostate Cancer: A Review of the Current Data.
    • Blas L, Shiota M, Eto M.
    • Cancers (Basel). 2022 Aug 27;14(17):4161. doi: 10.3390/cancers14174161.
    • Nijmegen Breakage Syndrome.
    • Varon R, Demuth I, Chrzanowska KH.
    • 1999 May 17 [updated 2022 Aug 18]. In: GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2022. Adam MP, Everman DB, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors.
    • Germline genetics of prostate cancer.
    • Khan HM, Cheng HH.
    • Prostate. 2022 Aug;82 Suppl 1:S3-S12. doi: 10.1002/pros.24340.
    • Insight into how patients with prostate cancer interpret and communicate genetic test results: implications for families.
    • Leader AE, Mercado J, Klein A, Hyatt C, Gross L, Brandt R, Giri VN.
    • J Community Genet. 2022 Jul 22. doi: 10.1007/s12687-022-00603-1. Epub ahead of print.
    • Genetic Testing and Its Clinical Application in Prostate Cancer Management: Consensus Statements from the Hong Kong Urological Association and Hong Kong Society of Uro-Oncology.
    • Chiu PKF, Lee EKC, Chan MTY, Chan WHC, Cheung MH, Lam MHC, Ma ESK, Poon DMC.
    • Front Oncol. 2022 Jul 18;12:962958. doi: 10.3389/fonc.2022.962958.

    Related:

    •• Commentary:

    Editorial: Prostate Cancer Genomics: Application at Different Stages of a Patient's Journey.

    • Genetic testing in prostate cancer management: Considerations informing primary care.
    • Giri VN, Morgan TM, Morris DS, Berchuck JE, Hyatt C, Taplin ME.
    • CA Cancer J Clin. 2022 Jul;72(4):360-371. doi: 10.3322/caac.21720. Epub 2022 Feb 24.
    • A Healthy Lifestyle in Men at Increased Genetic Risk for Prostate Cancer.
    • Plym A, Zhang Y, Stopsack KH, Delcoigne B, Wiklund F, Haiman C, Kenfield SA, Kibel AS, Giovannucci E, Penney KL, Mucci LA.
    • Eur Urol. 2022 May 27:S0302-2838(22)02342-9. doi: 10.1016/j.eururo.2022.05.008. Epub ahead of print.
    • Advances in urologic oncology "OncoUrology Forum Special Edition": The best of 2020.
    • Gómez-Veiga F, Alcaraz-Asensio A, Burgos-Revilla JM, Cózar-Olmo FJ.
    • Actas Urol Esp (Engl Ed). 2022 May;46(4):214-222. English, Spanish. doi: 10.1016/j.acuroe.2021.09.001. Epub 2021 Nov 26.
    • Review, Conference report
    • Volunteer Spotlight – Mike Philbin.
    • [No author given]
    • FORCE. Blog. 2022 Apr 29.
    • Clinical Management of Prostate Cancer in High-Risk Genetic Mutation Carriers.
    • Clark R, Herrera-Caceres J, Kenk M, Fleshner N.
    • Cancers (Basel). 2022 Feb 16;14(4):1004. doi: 10.3390/cancers14041004.
    • When to use germline genetic testing in prostate cancer.
    • Giri VN.
    • Clin Adv Hematol Oncol. 2022 Feb;20(2):78-81.
    • Genetic predisposition to prostate cancer: an update.
    • Ni Raghallaigh H, Eeles R.
    • Fam Cancer. 2022 Jan;21(1):101-114. doi: 10.1007/s10689-021-00227-3. Epub 2021 Jan 24.
    • PARP inhibitors and metastatic castration-resistant prostate cancer: uture directions and pitfalls.
    • Franza A, Claps M, Procopio G.
    • Transl Oncol. 2022 Jan;15(1):101263. doi: 10.1016/j.tranon.2021.101263. Epub 2021 Nov 8.
    • Updates in Prostate Cancer Research and Screening in Men at Genetically Higher Risk.
    • Bancroft EK, Raghallaigh HN, Page EC, Eeles RA.
    • Curr Genet Med Rep. 2021 [Dec];9(4):47-58. doi: 10.1007/s40142-021-00202-5. Epub 2021 Oct 8.
    • Germline Testing in Prostate Cancer: When and Who to Test.
    • Sokolova A, Cheng H.
    • Oncology (Williston Park). 2021 Oct 20;35(10):645-653. doi: 10.46883/ONC.2021.3510.0645.
    • Genetics of prostate cancer and its utility in treatment and screening.
    • Benafif S, Ni Raghallaigh H, McHugh J, Eeles R.
    • Adv Genet. 2021;108:147-199. doi: 10.1016/bs.adgen.2021.08.006. Epub 2021 Oct 19.
    • Review. Book chapter
    • Initial Findings from a High Genetic Risk Prostate Cancer Clinic.
    • Sessine MS, Das S, Park B, Salami SS, Kaffenberger SD, Kasputis A, Solorzano M, Luke M, Vince RA, Kaye DR, Borza T, Stoffel EM, Cobain E, Merajver SD, Jacobs MF, Milliron KJ, Caba L, van Neste L, Mondul AM, Morgan TM.
    • Urology. 2021 Oct;156:96-103. doi: 10.1016/j.urology.2021.05.078. Epub 2021 Jul 17.
    • A Different Kind of Trial: A Litigation Attorney's Take on Being in a National Institutes of Health Clinical Trial.
    • Hertz B.
    • FORCE. Blog. 2021 Sep 5.
    • Germline BRCA1 Mutation and Prostate Cancer: Be Careful on Causality.
    • Boilève A, Lavaud P, Caron O.
    • Eur Urol Oncol. 2021 Aug;4(4):674-675. doi: 10.1016/j.euo.2021.06.004. Epub 2021 Jun 19.
    • Letter, Comment

    Related:

    Review:

    Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer.

    • The evolving role of germline genetic testing and management in prostate cancer: Report from the Princess Margaret Cancer Centre International Retreat.
    • Clark R, Kenk M, McAlpine K, Thain E, Farncombe KM, Pritchard CC, Nussbaum R, Wyatt AW, de Bono J, Vesprini D, Bombard Y, Lorentz J, Narod S, Kim R, Fleshner N.
    • Can Urol Assoc J. 2021 Jun 22. doi: 10.5489/cuaj.7383. Epub ahead of print.
    • A Case-Based Clinical Approach to the Investigation, Management and Screening of Families with BRCA2 Related Prostate Cancer.
    • King B, McHugh J, Snape K.
    • Appl Clin Genet. 2021 May 20;14:255-266. doi: 10.2147/TACG.S261737.
    • A Clinical Trial of Prophylactic Prostatectomy for BRCA2 Mutation Carriers: Is Now the Time?
    • Clark R, McAlpine K, Fleshner N.
    • Eur Urol Focus. 2021 May;7(3):506-507. doi: 10.1016/j.euf.2021.04.018. Epub 2021 May 11.
    • Commentary. Study Protocol.
    • Risikoadaptierte Früherkennung des Prostatakarzinoms – Update 2021 [Risk-adapted prostate cancer screening-update 2021].
    • Al-Monajjed R, Arsov C, Albers P.
    • Urologe A. 2021 May;60(5):592-601. German. doi: 10.1007/s00120-021-01505-9. Epub 2021 Apr 1.
    • Review, [Article in German]
    • New advancements in cancer screenings bring hope for the future.
    • Meyer Krause C.
    • FORCE. Blog. 2021 Apr 23.

    Related:

    Research news: Update: FDA approves new imaging drug for detecting spread of prostate cancer. (FORCE. XRAY.)

    • Age-related activity of Poly (ADP-ribose) polymerase (PARP) in men with localized prostate cancer.
    • Deniz M, Zengerling F, Gundelach T, Moreno-Villanueva M, Bürkle A, Janni W, Bolenz C, Kostezka S, Marienfeld R, Benckendorff J, Friedl TWP, Wiesmüller L, Rall-Scharpf M.
    • Mech Ageing Dev. 2021 Apr 19:111494. doi: 10.1016/j.mad.2021.111494. Epub ahead of print.
    • Hereditary Prostate Cancer: Genes Related, Target Therapy and Prevention.
    • Vietri MT, D'Elia G, Caliendo G, Resse M, Casamassimi A, Passariello L, Albanese L, Cioffi M, Molinari AM.
    • Int J Mol Sci. 2021 Apr 4;22(7):3753. doi: 10.3390/ijms22073753.
    • Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer.
    • Lozano R, Castro E, Aragón IM, Cendón Y, Cattrini C, López-Casas PP, Olmos D.
    • Br J Cancer. 2021 Feb;124(3):552-563. doi: 10.1038/s41416-020-01114-x. Epub 2020 Oct 27.
    • EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.
    • Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, Fanti S, Fossati N, Gandaglia G, Gillessen S, Grivas N, Grummet J, Henry AM, van der Kwast TH, Lam TB, Lardas M, Liew M, Mason MD, Moris L, Oprea-Lager DE, van der Poel HG, Rouvière O, Schoots IG, Tilki D, Wiegel T, Willemse PM, Cornford P.
    • Eur Urol. 2021 Feb;79(2):243-262. doi: 10.1016/j.eururo.2020.09.042. Epub 2020 Nov 7.
    • Guidelines, Review
    • Germline pathogenic variants in the Ataxia Telangiectasia Mutated (ATM) gene are associated with high and moderate risks for multiple cancers.
    • Hall MJ, Bernhisel R, Hughes E, Larson K, Rosenthal ET, Singh NA, Lancaster JM, Kurian AW.
    • Cancer Prev Res (Phila). 2021 Jan 28:canprevres.0448.2020. doi: 10.1158/1940-6207.CAPR-20-0448. Epub ahead of print.
    • Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
    • Daly MB, Pal T, Berry MP, Buys SS, Dickson P, Domchek SM, Elkhanany A, Friedman S, Goggins M, Hutton ML; CGC, Karlan BY, Khan S, Klein C, Kohlmann W; CGC, Kurian AW, Laronga C, Litton JK, Mak JS; LCGC, Menendez CS, Merajver SD, Norquist BS, Offit K, Pederson HJ, Reiser G; CGC, Senter-Jamieson L; CGC, Shannon KM, Shatsky R, Visvanathan K, Weitzel JN, Wick MJ, Wisinski KB, Yurgelun MB, Darlow SD, Dwyer MA.
    • J Natl Compr Canc Netw. 2021 Jan 6;19(1):77-102. doi: 10.6004/jnccn.2021.0001.
    • Association between prostate cancer characteristics and BRCA1/2-associated family cancer history in a Japanese cohort.
    • Ishiyama Y, Shimbo M, Iizuka J, Deshpande G, Tanabe K, Hattori K.
    • PLoS One. 2020 Dec 22;15(12):e0244149. doi: 10.1371/journal.pone.0244149.
    • DNA damage repair gene mutation testing and genetic counseling in men with/without prostate cancer: a systematic review.
    • Armstrong N, Quek RG, Ryder S, Ross J, Titas Buksnys, Forbes C, Fox KM, Castro E.
    • Future Oncol. 2020 Dec 2. doi: 10.2217/fon-2020-0569. Epub ahead of print.
    • Review
    • Knowledge and practice regarding prostate cancer germline testing among urologists: Gaps to address for optimal implementation.
    • Loeb S, Byrne N, Walter D, Makarov DV, Wise DR, Becker D, Giri VN.
    • Cancer Treat Res Commun. 2020 Sep 28;25:100212. doi: 10.1016/j.ctarc.2020.100212. Epub ahead of print.
    • Invitae Launches Study to Explore Impact of Testing Guidelines on Prostate Cancer Patients' Outcomes.
    • [No author given]
    • Precision Oncology News. 2020 Sep 3.
    • Imaging-based prostate cancer screening among BRCA mutation carriers-results from the first round of screening.
    • Segal N, Ber Y, Benjaminov O, Tamir S, Yakimov M, Kedar I, Rosenbaum E, Sela S, Ozalvo R, Shavit-Grievink L, Keder D, Baniel J, Margel D.
    • Ann Oncol. 2020 Aug 27:S0923-7534(20)39937-3. doi: 10.1016/j.annonc.2020.06.025. Epub ahead of print.
    • Germline mutations and prostate cancer: is it time to change treatment algorithms?
    • Telvizian T, Mukherji D.
    • Chin Clin Oncol. 2020 Aug 27:cco-19-207. doi: 10.21037/cco-19-207. Epub ahead of print.
    • Germlines 'Rich Source' of Prostate Cancer Info.
    • O'Rourke K, Giri V.
    • Medscape Oncology. 2020 Jul 21.
    • Hereditary Predisposition to Prostate Cancer: From Genetics to Clinical Implications.
    • Brandão A, Paulo P, Teixeira MR.
    • Int J Mol Sci. 2020 Jul 16;21(14):E5036. doi: 10.3390/ijms21145036.
    • Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer.
    • van der Doelen MJ, Isaacsson Velho P, Slootbeek PHJ, Pamidimarri Naga S, Bormann M, van Helvert S, Kroeze LI, van Oort IM, Gerritsen WR, Antonarakis ES, Mehra N.
    • Eur J Cancer. 2020 Jul 4;136:16-24. doi: 10.1016/j.ejca.2020.05.001. Epub ahead of print.
    • Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).
    • Silvestri V, Leslie G, Barnes DR; and the CIMBA Group, Agnarsson BA, Aittomäki K, Alducci E, Andrulis IL, Barkardottir RB, Barroso A, Barrowdale D, Benitez J, Bonanni B, Borg A, Buys SS, Caldés T, Caligo MA, Capalbo C, Campbell I, Chung WK, Claes KBM, Colonna SV, Cortesi L, Couch FJ, de la Hoya M, Diez O, Ding YC, Domchek S, Easton DF, Ejlertsen B, Engel C, Evans DG, Feliubadalò L, Foretova L, Fostira F, Géczi L, Gerdes AM, Glendon G, Godwin AK, Goldgar DE, Hahnen E, Hogervorst FBL, Hopper JL, Hulick PJ, Isaacs C, Izquierdo A, James PA, Janavicius R, Jensen UB, John EM, Joseph V, Konstantopoulou I, Kurian AW, Kwong A, Landucci E, Lesueur F, Loud JT, Machackova E, Mai PL, Majidzadeh-A K, Manoukian S, Montagna M, Moserle L, Mulligan AM, Nathanson KL, Nevanlinna H, Ngeow Yuen Ye J, Nikitina-Zake L, Offit K, Olah E, Olopade OI, Osorio A, Papi L, Park SK, Pedersen IS, Perez-Segura P, Petersen AH, Pinto P, Porfirio B, Pujana MA, Radice P, Rantala J, Rashid MU, Rosenzweig B, Rossing M, Santamariña M, Schmutzler RK, Senter L, Simard J, Singer CF, Solano AR, Southey MC, Steele L, Steinsnyder Z, Stoppa-Lyonnet D, Tan YY, Teixeira MR, Teo SH, Terry MB, Thomassen M, Toland AE, Torres-Esquius S, Tung N, van Asperen CJ, Vega A, Viel A, Vierstraete J, Wappenschmidt B, Weitzel JN, Wieme G, Yoon SY, Zorn KK, McGuffog L, Parsons MT, Hamann U, Greene MH, Kirk JA, Neuhausen SL, Rebbeck TR, Tischkowitz M, Chenevix-Trench G, Antoniou AC, Friedman E, Ottini L.
    • JAMA Oncol. 2020 Jul 2. doi: 10.1001/jamaoncol.2020.2134. Epub ahead of print.
    • Cancer Surveillance in Healthy Carriers of Germline Pathogenic Variants in BRCA1/2: A Review of Secondary Prevention Guidelines.
    • Dullens B, de Putter R, Lambertini M, Toss A, Han S, Van Nieuwenhuysen E, Van Gorp T, Vanderstichele A, Van Ongeval C, Keupers M, Prevos R, Celis V, Dekervel J, Everaerts W, Wildiers H, Nevelsteen I, Neven P, Timmerman D, Smeets A, Denayer E, Van Buggenhout G, Legius E, Punie K.
    • J Oncol. 2020 Jun 20;2020:9873954. doi: 10.1155/2020/9873954.
    • Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019.
    • Giri VN, Knudsen KE, Kelly WK, Cheng HH, Cooney KA, Cookson MS, Dahut W, Weissman S, Soule HR, Petrylak DP, Dicker AP, AlDubayan SH, Toland AE, Pritchard CC, Pettaway CA, Daly MB, Mohler JL, Parsons JK, Carroll PR, Pilarski R, Blanco A, Woodson A, Rahm A, Taplin ME, Polascik TJ, Helfand BT, Hyatt C, Morgans AK, Feng F, Mullane M, Powers J, Concepcion R, Lin DW, Wender R, Mark JR, Costello A, Burnett AL, Sartor O, Isaacs WB, Xu J, Weitzel J, Andriole GL, Beltran H, Briganti A, Byrne L, Calvaresi A, Chandrasekar T, Chen DYT, Den RB, Dobi A, Crawford ED, Eastham J, Eggener S, Freedman ML, Garnick M, Gomella PT, Handley N, Hurwitz MD, Izes J, Karnes RJ, Lallas C, Languino L, Loeb S, Lopez AM, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann M, Mille P, Miner MM, Morgan T, Moreno J, Mucci L, Myers RE, Nielsen SM, O'Neil B, Pinover W, Pinto P, Poage W, Raj GV, Rebbeck TR, Ryan C, Sandler H, Schiewer M, Scott EMD, Szymaniak B, Tester W, Trabulsi EJ, Vapiwala N, Yu EY, Zeigler-Johnson C, Gomella LG.
    • J Clin Oncol. 2020 Jun 9:JCO2000046. doi: 10.1200/JCO.20.00046. Epub ahead of print.

    Related:

    Press: Cancer Experts Develop Precision Medicine-Based Genetic Testing Framework for Prostate Cancer. (GenomeWeb)

    Press: Consider Genetic Testing in All Metastatic Prostate Cancers. (MedPage Today)

    • Risk of Prostate Cancer Associated With Familial and Hereditary Cancer Syndromes.
    • Beebe-Dimmer JL, Kapron AL, Fraser AM, Smith KR, Cooney KA.
    • J Clin Oncol. 2020 Mar 24:JCO1902808. doi: 10.1200/JCO.19.02808. [Epub ahead of print]
    • Male Breast Cancer: Surgical and Genetic Features and a Multidisciplinary Management Strategy.
    • Pellini F, Granuzzo E, Urbani S, Mirandola S, Caldana M, Lombardi D, Fiorio E, Mandarà M, Pollini GP.
    • Breast Care (Basel). 2020 Feb;15(1):14-20. doi: 10.1159/000501711. Epub 2019 Sep 13.
    • Genetic Testing in Prostate Cancer.
    • Sokolova AO, Cheng HH.
    • Curr Oncol Rep. 2020 Jan 23;22(1):5. doi: 10.1007/s11912-020-0863-6.
    • Review
    • Hereditary prostate cancer - Primetime for genetic testing?
    • Heidegger I, Tsaur I, Borgmann H, Surcel C, Kretschmer A, Mathieu R, Visschere P, Valerio M, van den Bergh RCN, Ost P, Tilki D, Gandaglia G, Ploussard G; EAU-YAU Prostate Cancer Working Party.
    • Cancer Treat Rev. 2019 Nov 11;81:101927. doi: 10.1016/j.ctrv.2019.101927. [Epub ahead of print]
    • Review
    • Men With BRCA2 Should Be Screened for Prostate Cancer.
    • Davenport L.
    • Medscape Oncology. 2019 Nov 8.

    Related:

    Original research:

    Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers.

    • The IMPACT of BRCA2 in prostate cancer.
    • Stone L.
    • Nat Rev Urol. 2019 Nov;16(11):639. doi: 10.1038/s41585-019-0249-4.

    Related:

    Original research:

    Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers.

    • How Do We Respond to Men with BRCA Mutations when They Ask About Prostate Cancer?
    • Karzai F, Madan RA, Dahut WL.
    • Eur Urol. 2019 Oct 29. pii: S0302-2838(19)30767-5. doi: 10.1016/j.eururo.2019.10.001. [Epub ahead of print]
    • Editorial
    • A first Japanese case of neuroendocrine prostate cancer accompanied by lung and brain metastasis with somatic and germline BRCA2 mutation.
    • Kosaka T, Hongo H, Aimono E, Matsumoto K, Hayashida T, Mikami S, Nishihara H, Oya M.
    • Pathol Int. 2019 Oct 20. doi: 10.1111/pin.12860. [Epub ahead of print]
    • Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers.
    • Page EC, Bancroft EK, Brook MN, Assel M, Hassan Al Battat M, Thomas S, Taylor N, Chamberlain A, Pope J, Raghallaigh HN, Evans DG, Rothwell J, Mahle L, Grindedal EMM, James P, Mascarenhas L, McKinley J, Side L, Thomas T, van Asperen C, Vasen H, Kiemeney LA, Ringelberg J, Jensen TD, Osther PJS, Helfand BT, Genova E, Oldenburg RA, Cybulski C, Wokolorczyk D, Ong KR, Huber C, Lam J, Taylor L, Salinas M, Feliubadaló L, Oosterwijk JC, van Zelst-Stams W, Cook J, Rosario DJ, Domchek S, Powers J, Buys S, O'Toole K, Ausems MGEM, Schmutzler RK, Rhiem K, Izatt L, Tripathi V, Teixeira MR, Cardoso M, Foulkes WD, Aprikian A, van Randeraad H, Davidson R, Longmuir M, Ruijs MWG, Helderman van den Enden ATJM, Adank M, Williams R, Andrews L, Murphy DG, Halliday D, Walker L, Liljegren A, Carlsson S, Azzabi A, Jobson I, Morton C, Shackleton K, Snape K, Hanson H, Harris M, Tischkowitz M, Taylor A, Kirk J, Susman R, Chen-Shtoyerman R, Spigelman A, Pachter N, Ahmed M, Ramon Y Cajal T, Zgajnar J, Brewer C, Gadea N, Brady AF, van Os T, Gallagher D, Johannsson O, Donaldson A, Barwell J, Nicolai N, Friedman E, Obeid E, Greenhalgh L, Murthy V, Copakova L, Saya S, McGrath J, Cooke P, Rønlund K, Richardson K, Henderson A, Teo SH, Arun B, Kast K, Dias A, Aaronson NK, Ardern-Jones A, Bangma CH, Castro E, Dearnaley D, Eccles DM, Tricker K, Eyfjord J, Falconer A, Foster C, Gronberg H, Hamdy FC, Stefansdottir V, Khoo V, Lindeman GJ, Lubinski J, Axcrona K, Mikropoulos C, Mitra A, Moynihan C, Rennert G, Suri M, Wilson P, Dudderidge T; IMPACT Study Collaborators, Offman J, Kote-Jarai Z, Vickers A, Lilja H, Eeles RA.
    • Eur Urol. 2019 Sep 12. pii: S0302-2838(19)30668-2. doi: 10.1016/j.eururo.2019.08.019. [Epub ahead of print]

    Related:

    Research news, Conference report: Men With BRCA2 Should Be Screened for Prostate Cancer. (Medscape)

    Research news: The IMPACT of BRCA2 in prostate cancer. (Nature Reviews Urology)

    • Bringing Prostate Cancer Germline Genetics into Clinical Practice.
    • Das S, Salami SS, Spratt DE, Kaffenberger SD, Jacobs MF, Morgan TM.
    • J Urol. 2019 Aug;202(2):223-230. doi: 10.1097/JU.0000000000000137. Epub 2019 Jul 8.
    • Risk Prediction Tools Available for Germline BRCA1/2 Mutations Underperform in Prostate Cancer Patients.
    • Oliva L, Lozano R, Llácer C, Aragón I, Pajares BI, Sáez MI, Herrera-Imbroda B, Montesa A, Hernández D, Villatoro R, Otero A, Correa R, Grau G, Peinado P, Pacheco MI, García-Galisteo E, Rueda A, Machuca FJ, Alba E, Márquez-Aragonés A, Olmos D, Castro E.
    • Eur Urol Oncol. 2019 Jul 12. pii: S2588-9311(19)30100-2. doi: 10.1016/j.euo.2019.06.019. [Epub ahead of print]
    • Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Prostate Cancer
    • Srinivas S, Shah SA.
    • NCCN Continuing Education. 2019 Jul 5.
    • CME Course
    • Screening, Active Surveillance, and Treatment of Localized Prostate Cancer Among Carriers of Germline BRCA Mutations.
    • Halstuch D, Ber Y, Margel D.
    • Eur Urol Focus. 2019 May 27. pii: S2405-4569(19)30146-4. doi: 10.1016/j.euf.2019.05.009. [Epub ahead of print]
    • Review
    • Germline and Somatic Mutations in Prostate Cancer for the Clinician.
    • Cheng HH, Sokolova AO, Schaeffer EM, Small EJ, Higano CS.
    • J Natl Compr Canc Netw. 2019 May 1;17(5):515-521. doi: 10.6004/jnccn.2019.7307.
    • Germline Mutations in ATM and BRCA1/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer.
    • Carter HB, Helfand B, Mamawala M, Wu Y, Landis P, Yu H, Wiley K, Na R, Shi Z, Petkewicz J, Shah S, Fantus RJ, Novakovic K, Brendler CB, Zheng SL, Isaacs WB, Xu J.
    • Eur Urol. 2019 May;75(5):743-749. doi: 10.1016/j.eururo.2018.09.021. Epub 2018 Oct 8.

    Related:

    Research news: DNA-Repair- Gene Mutations Linked to More Aggressive Prostate Cancer. (Medscape Oncology)

    • BRCA2 and Other DDR Genes in Prostate Cancer.
    • Nombela P, Lozano R, Aytes A, Mateo J, Olmos D, Castro E.
    • Cancers (Basel). 2019 Mar 12;11(3). pii: E352. doi: 10.3390/cancers11030352.
    • Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing.
    • Giri VN, Hegarty SE, Hyatt C, O'Leary E, Garcia J, Knudsen KE, Kelly WK, Gomella LG.
    • Prostate. 2019 Mar;79(4):333-339. doi: 10.1002/pros.23739. Epub 2018 Nov 18.
    • Metastatic Prostate Cancer: Effects of Genetic Testing on Care.
    • Connors LM.
    • Clin J Oncol Nurs. 2019 Feb 1;23(1):32-35. doi: 10.1188/19.CJON.32-35.
    • Review
    • Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations.
    • Bancroft EK, Saya S, Page EC, Myhill K, Thomas S, Pope J, Chamberlain A, Hart R, Glover W, Cook J, Rosario DJ, Helfand BT, Hutten Selkirk C, Davidson R, Longmuir M, Eccles DM, Gadea N, Brewer C, Barwell J, Salinas M, Greenhalgh L, Tischkowitz M, Henderson A, Evans DG, Buys SS; IMPACT Study Steering Committee; IMPACT Collaborators, Eeles RA, Aaronson NK.
    • BJU Int. 2019 Feb;123(2):284-292. doi: 10.1111/bju.14412. Epub 2018 Jun 22.
    • The Role of BRCA Testing in Hereditary Pancreatic and Prostate Cancer Families.
    • Pilarski R.
    • Am Soc Clin Oncol Educ Book. 2019 Jan;(39):79-86. doi: 10.1200/EDBK_238977.
    • Aberrations of DNA Repair Pathways in Prostate Cancer: Future Implications for Clinical Practice?
    • Caffo O, Veccia A, Kinspergher S, Rizzo M, Maines F.
    • Front Cell Dev Biol. 2018 Sep 5;6:71. doi: 10.3389/fcell.2018.00071. eCollection 2018.
    • Prostate Cancer Germline Variations and Implications for Screening and Treatment.
    • Dias A, Kote-Jarai Z, Mikropoulos C, Eeles R.
    • Cold Spring Harb Perspect Med. 2018 Sep 4;8(9). pii: a030379. doi: 10.1101/cshperspect.a030379.
    • Review
    • The resounding effect of DNA repair deficiency in prostate cancer.
    • Cheng HH.
    • Urol Oncol. 2018 Aug;36(8):385-388. doi: 10.1016/j.urolonc.2018.02.014. Epub 2018 Mar 17.
    • Review
    • DNA Damage Repair (DDR) Mutations and the Utility of High-Risk Genetics Clinics in Metastatic Castration-Refractory Prostate Cancer (mCRPC).
    • Rathi N, Anderson N, Greenberg S, Vagher J, Agarwal N, Hahn AW.
    • World J Oncol. 2018 Aug;9(4):119-122. doi: 10.14740/wjon1144w. Epub 2018 Sep 6.
    • Malignant Abnormalities in Male BRCA Mutation Carriers: Results From a Prospectively Screened Cohort.
    • Mano R, Tamir S, Kedar I, Benjaminov O, Baniel J, Tabachnik T, Margel D.
    • JAMA Oncol. 2018 Jun 1;4(6):872-874. doi: 10.1001/jamaoncol.2018.0271.
    • Practical Methods for Integrating Genetic Testing Into Clinical Practice for Advanced Prostate Cancer.
    • Cheng H, Powers J, Schaffer K, Sartor O.
    • Am Soc Clin Oncol Educ Book. 2018 May 23;(38):372-381. doi: 10.1200/EDBK_205441.
    • Germline BRCA mutation in male carriers-ripe for precision oncology?
    • Leão RRN, Price AJ, James Hamilton R.
    • Prostate Cancer Prostatic Dis. 2018 Apr;21(1):48-56. doi: 10.1038/s41391-017-0018-5. Epub 2017 Dec 14.
    • Review
    • Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017.
    • Giri VN, Knudsen KE, Kelly WK, Abida W, Andriole GL, Bangma CH, Bekelman JE, Benson MC, Blanco A, Burnett A, Catalona WJ, Cooney KA, Cooperberg M, Crawford DE, Den RB, Dicker AP, Eggener S, Fleshner N, Freedman ML, Hamdy FC, Hoffman-Censits J, Hurwitz MD, Hyatt C, Isaacs WB, Kane CJ, Kantoff P, Karnes RJ, Karsh LI, Klein EA, Lin DW, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann MJ, Mark JR, McCue PA, Miner MM, Morgan T, Moul JW, Myers RE, Nielsen SM, Obeid E, Pavlovich CP, Peiper SC, Penson DF, Petrylak D, Pettaway CA, Pilarski R, Pinto PA, Poage W, Raj GV, Rebbeck TR, Robson ME, Rosenberg MT, Sandler H, Sartor O, Schaeffer E, Schwartz GF, Shahin MS, Shore ND, Shuch B, Soule HR, Tomlins SA, Trabulsi EJ, Uzzo R, Vander Griend DJ, Walsh PC, Weil CJ, Wender R, Gomella LG.
    • J Clin Oncol. 2018 Feb 1;36(4):414-424. doi: 10.1200/JCO.2017.74.1173. Epub 2017 Dec 13.
    • Men with a susceptibility to prostate cancer and the role of genetic based screening.
    • Eeles R, Ni Raghallaigh H.
    • Transl Androl Urol. 2018 Feb;7(1):61-69. doi: 10.21037/tau.2017.12.30.
    • Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition.
    • Mikropoulos C, Selkirk CGH, Saya S, Bancroft E, Vertosick E, Dadaev T, Brendler C, Page E, Dias A, Evans DG, Rothwell J, Maehle L, Axcrona K, Richardson K, Eccles D, Jensen T, Osther PJ, van Asperen CJ, Vasen H, Kiemeney LA, Ringelberg J, Cybulski C, Wokolorczyk D, Hart R, Glover W, Lam J, Taylor L, Salinas M, Feliubadaló L, Oldenburg R, Cremers R, Verhaegh G, van Zelst-Stams WA, Oosterwijk JC, Cook J, Rosario DJ, Buys SS, Conner T, Domchek S, Powers J, Ausems MG, Teixeira MR, Maia S, Izatt L, Schmutzler R, Rhiem K, Foulkes WD, Boshari T, Davidson R, Ruijs M, Helderman-van den Enden AT, Andrews L, Walker L, Snape K, Henderson A, Jobson I, Lindeman GJ, Liljegren A, Harris M, Adank MA, Kirk J, Taylor A, Susman R, Chen-Shtoyerman R, Pachter N, Spigelman A, Side L, Zgajnar J, Mora J, Brewer C, Gadea N, Brady AF, Gallagher D, van Os T, Donaldson A, Stefansdottir V, Barwell J, James PA, Murphy D, Friedman E, Nicolai N, Greenhalgh L, Obeid E, Murthy V, Copakova L, McGrath J, Teo SH, Strom S, Kast K, Leongamornlert DA, Chamberlain A, Pope J, Newlin AC, Aaronson N, Ardern-Jones A, Bangma C, Castro E, Dearnaley D, Eyfjord J, Falconer A, Foster CS, Gronberg H, Hamdy FC, Johannsson O, Khoo V, Lubinski J, Grindedal EM, McKinley J, Shackleton K, Mitra AV, Moynihan C, Rennert G, Suri M, Tricker K; IMPACT study collaborators, Moss S, Kote-Jarai Z, Vickers A, Lilja H, Helfand BT, Eeles RA.
    • Br J Cancer. 2018 Jan;118(2):266-276. doi: 10.1038/bjc.2017.429. Epub 2018 Jan 4.
    • Prostate Cancer Screening in a New Era of Genetics.
    • Cheng HH, Pritchard CC, Montgomery B, Lin DW, Nelson PS.
    • Clin Genitourin Cancer. 2017 Dec;15(6):625-628. doi: 10.1016/j.clgc.2017.05.024. Epub 2017 May 31.
    • Review
    • Lower Urinary Tract Symptoms and Benign Prostate Hyperplasia Features Among Male BRCA Mutation Carriers.
    • Goldberg H, Grievink LS, Mano R, Ber Y, Ozalbo R, Tuval S, Baniel J, Margel D.
    • Urology. 2017 Oct;108:71-75. doi: 10.1016/j.urology.2017.05.036. Epub 2017 May 31.
    • Relevance of DNA damage repair in the management of prostate cancer.
    • Banks P, Xu W, Murphy D, James P, Sandhu S.
    • Curr Probl Cancer. 2017 Jul - Aug;41(4):287-301. doi: 10.1016/j.currproblcancer.2017.06.001. Epub 2017 Jun 27.
    • Review
    • Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer.
    • Annala M, Struss WJ, Warner EW, Beja K, Vandekerkhove G, Wong A, Khalaf D, Seppälä IL, So A, Lo G, Aggarwal R, Small EJ, Nykter M, Gleave ME, Chi KN, Wyatt AW.
    • Eur Urol. 2017 Jul;72(1):34-42. doi: 10.1016/j.eururo.2017.02.023. Epub 2017 Mar 1.
    • 5 Big Questions (and Answers) on Inherited Prostate Cancer Testing.
    • Nick Mulcahy
    • Medscape. Coverage from the American Urological Association (AUA) 2017 Annual Meeting. 2017 May 18.
    • EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.
    • Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, Fossati N, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, Matveev VB, Moldovan PC, van den Bergh RC, Van den Broeck T, van der Poel HG, van der Kwast TH, Rouvière O, Schoots IG, Wiegel T, Cornford P.
    • Eur Urol. 2017 Apr;71(4):618-629. doi: 10.1016/j.eururo.2016.08.003. Epub 2016 Aug 25.
    • Conference Report, Review
    • Screening men at increased risk for prostate cancer diagnosis: Model estimates of benefits and harms.
    • Gulati R, Cheng HH, Lange PH, Nelson PS, Etzioni R.
    • Cancer Epidemiol Biomarkers Prev. 2017 Feb;26(2):222-227. doi: 10.1158/1055-9965.EPI-16-0434. Epub 2016 Oct 14.
    • Prevention and Screening in Hereditary Breast and Ovarian Cancer.
    • Zeichner SB, Stanislaw C, Meisel JL.
    • Oncology (Williston Park). 2016 Oct 15;30(10). pii: 219285.

    Related:

    Commentary

    Clinical Hereditary Cancer Syndromes and Gene Panel Testing.

    • Implications of High Rates of Metastatic Prostate Cancer in BRCA2 Mutation Carriers.
    • Gleicher S, Kauffman EC, Kotula L, Bratslavsky G, Vourganti S.
    • Prostate. 2016 Sep;76(13):1135-45. doi: 10.1002/pros.23204. Epub 2016 May 26.
    • Meta-Analysis, Review
    • Biallelic BRCA2 Mutations Shape the Somatic Mutational Landscape of Aggressive Prostate Tumors.
    • Decker B, Karyadi DM, Davis BW, Karlins E, Tillmans LS, Stanford JL, Thibodeau SN, Ostrander EA.
    • Am J Hum Genet. 2016 May 5;98(5):818-829. doi: 10.1016/j.ajhg.2016.03.003. Epub 2016 Apr 14.
    • NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016.
    • Carroll PR, Parsons JK, Andriole G, Bahnson RR, Castle EP, Catalona WJ, Dahl DM, Davis JW, Epstein JI, Etzioni RB, Farrington T, Hemstreet GP 3rd, Kawachi MH, Kim S, Lange PH, Loughlin KR, Lowrance W, Maroni P, Mohler J, Morgan TM, Moses KA, Nadler RB, Poch M, Scales C, Shaneyfelt TM, Smaldone MC, Sonn G, Sprenkle P, Vickers AJ, Wake R, Shead DA, Freedman-Cass DA.
    • J Natl Compr Canc Netw. 2016 May;14(5):509-19.
    • Caring for Patients With Prostate Cancer Who Are BRCA Positive.
    • Hartzfeld D, Berse B, Lowrance W, Dash A, Brawer M, Lawrence J, Meyer L, Lynch J.
    • Fed Pract. 2016 Feb;33(Suppl 1):46S-51S.
    • [Hereditary Breast and Ovarian Cancer Syndrome].
    • Petráková K, Palácová M, Schneiderová M, Standara M.
    • Klin Onkol. 2015 Winter;29 Suppl 1:14-21.
    • Review, [Article in Czech]
    • High burden of copy number alterations and c-MYC amplification in prostate cancer from BRCA2 germline mutation carriers.
    • Castro E, Jugurnauth-Little S, Karlsson Q, Al-Shahrour F, Piñeiro-Yañez E, Van de Poll F, Leongamornlert D, Dadaev T, Govindasami K, Guy M, Eeles R, Kote-Jarai Z; UKGPCS, EMBRACE and IMPACT studies.
    • Ann Oncol. 2015 Nov;26(11):2293-300. doi: 10.1093/annonc/mdv356. Epub 2015 Sep 7.
    • The role of the prostate cancer gene 3 urine test in addition to serum prostate-specific antigen level in prostate cancer screening among breast cancer, early-onset gene mutation carriers.
    • Cremers RG, Eeles RA, Bancroft EK, Ringelberg-Borsboom J, Vasen HF, Van Asperen CJ; IMPACT Steering Committee, Schalken JA, Verhaegh GW, Kiemeney LA.
    • Urol Oncol. 2015 May;33(5):202.e19-28. doi: 10.1016/j.urolonc.2015.01.018. Epub 2015 Mar 5.
    • Prostate cancer screening characteristics in men with BRCA1/2 mutations attending a high-risk prevention clinic.
    • Walker R, Louis A, Berlin A, Horsburgh S, Bristow RG, Trachtenberg J.
    • Can Urol Assoc J. 2014 Nov;8(11-12):E783-8. doi: 10.5489/cuaj.1970.
    • BRCA and Men: Medical Management and Prostate-specific Considerations.
    • Jacquelyn Powers.
    • FORCE. Be Empowered Webinars. 2014 Oct 1.
    • Hormonal and Surgical Treatment in Trans-Women with BRCA1 Mutations: A Controversial Topic.
    • Colebunders B, T'Sjoen G, Weyers S, Monstrey S.
    • J Sex Med. 2014 Oct;11(10):2496-9. doi: 10.1111/jsm.12628. Epub 2014 Jul 10.
    • Case report

    Related:

    Comments from NSGC Discussion Forum Cancer SIG

    Subject: Cancer risks for transgender patient

    • Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study.
    • Bancroft EK, Page EC, Castro E, Lilja H, Vickers A, Sjoberg D, Assel M, Foster CS, Mitchell G, Drew K, Mæhle L, Axcrona K, Evans DG, Bulman B, Eccles D, McBride D, van Asperen C, Vasen H, Kiemeney LA, Ringelberg J, Cybulski C, Wokolorczyk D, Selkirk C, Hulick PJ, Bojesen A, Skytte AB, Lam J, Taylor L, Oldenburg R, Cremers R, Verhaegh G, van Zelst-Stams WA, Oosterwijk JC, Blanco I, Salinas M, Cook J, Rosario DJ, Buys S, Conner T, Ausems MG, Ong KR, Hoffman J, Domchek S, Powers J, Teixeira MR, Maia S, Foulkes WD, Taherian N, Ruijs M, Helderman-van den Enden AT, Izatt L, Davidson R, Adank MA, Walker L, Schmutzler R, Tucker K, Kirk J, Hodgson S, Harris M, Douglas F, Lindeman GJ, Zgajnar J, Tischkowitz M, Clowes VE, Susman R, Ramón y Cajal T, Patcher N, Gadea N, Spigelman A, van Os T, Liljegren A, Side L, Brewer C, Brady AF, Donaldson A, Stefansdottir V, Friedman E, Chen-Shtoyerman R, Amor DJ, Copakova L, Barwell J, Giri VN, Murthy V, Nicolai N, Teo SH, Greenhalgh L, Strom S, Henderson A, McGrath J, Gallagher D, Aaronson N, Ardern-Jones A, Bangma C, Dearnaley D, Costello P, Eyfjord J, Rothwell J, Falconer A, Gronberg H, Hamdy FC, Johannsson O, Khoo V, Kote-Jarai Z, Lubinski J, Axcrona U, Melia J, McKinley J, Mitra AV, Moynihan C, Rennert G, Suri M, Wilson P, Killick E; IMPACT Collaborators, Moss S, Eeles RA.
    • Eur Urol. 2014 Sep;66(3):489-99. doi: 10.1016/j.eururo.2014.01.003. Epub 2014 Jan 15.

    Related:

    Comment:

    Prostate cancer: What is the real IMPACT of BRCA1/BRCA2 mutation?

    Editorial/Commentary:

    The clinical impact of genetic susceptibility to prostate cancer.

    • Aspirin Use is Associated with Lower Prostate Cancer Risk in Male Carriers of BRCA Mutations.
    • Cossack M, Ghaffary C, Watson P, Snyder C, Lynch H.
    • J Genet Couns. 2014 Apr;23(2):187-91. doi: 10.1007/s10897-013-9629-8. Epub 2013 Jul 25.
    • Prostate cancer: What is the real IMPACT of BRCA1/BRCA2 mutation?
    • Clyne M.
    • Nat Rev Urol. 2014 Mar;11(3):124. doi: 10.1038/nrurol.2014.19. Epub 2014 Feb 4.
    • Editorial / Commentary

    Related:

    Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study.

    • Clinical features and management of BRCA1 and BRCA2-associated prostate cancer.
    • Alanee SR, Glogowski EA, Schrader KA, Eastham JA, Offit K.
    • Front Biosci (Elite Ed). 2014 Jan 1;6:15-30.
    • Optimizing recruitment to a prostate cancer surveillance program among male BRCA1 mutation carriers: invitation by mail or by telephone.
    • Galor A, Cybulski C, Lubiński J, Narod SA, Gronwald J.
    • Hered Cancer Clin Pract. 2013 Dec 10;11(1):17. doi: 10.1186/1897-4287-11-17.
    • Interest of individuals from BRCA families to participate in research studies focused on male BRCA carriers.
    • Pal T, Vadaparampil S, Kim J, Xu Y, Friedman S, Narod SA, Metcalfe K.
    • Fam Cancer. 2013 Dec;12(4):615-9. doi: 10.1007/s10689-013-9624-0.
    • A personalised approach to prostate cancer screening based on genotyping of risk founder alleles.
    • Cybulski C, Wokołorczyk D, Kluźniak W, Kashyap A, Gołąb A, Słojewski M, Sikorski A, Puszyński M, Soczawa M, Borkowski T, Borkowski A, Antczak A, Przybyła J, Sosnowski M, Małkiewicz B, Zdrojowy R, Domagała P, Piotrowski K, Menkiszak J, Krzystolik K, Gronwald J, Jakubowska A, Górski B, Dębniak T, Masojć B, Huzarski T, Muir KR, Lophatananon A, Lubiński J, Narod SA; Polish Hereditary Prostate Cancer Consortium.
    • Br J Cancer. 2013 Jun 25;108(12):2601-9. doi: 10.1038/bjc.2013.261. Epub 2013 May 30.
    • The role of BRCA1 and BRCA2 in prostate cancer.
    • Li D, Kumaraswamy E, Harlan-Williams LM, Jensen RA.
    • Front Biosci (Landmark Ed). 2013 Jun 1;18:1445-59.
    • First Man Has Prostatectomy Because of BRCA Gene Mutation.
    • Zosia Chustecka.
    • Medscape Medical News. Oncology. 2013 May 20.
    • Familial prostate cancer: the damage done and lessons learnt.
    • Taherian N, Hamel N, Bégin LR, Bismar TA, Goldgar DE, Feng BJ, Foulkes WD.
    • Nat Rev Urol. 2013 Feb;10(2):116-22. doi: 10.1038/nrurol.2012.257. Epub 2013 Jan 15.
    • Prostate cancer screening in BRCA and Lynch syndrome mutation carriers.
    • Castro E, Goh CL, Eeles RA.
    • Am Soc Clin Oncol Educ Book. 2013. doi: 10.1200/EdBook_AM.2013.33.e50.
    • High grade prostatic intraepithelial neoplasia does not display loss of heterozygosity at the mutation locus in BRCA2 mutation carriers with aggressive prostate cancer.
    • Willems-Jones A, Kavanagh L, Clouston D, Bolton D; kConFab Investigators, Fox S, Thorne H.
    • BJU Int. 2012 Dec;110(11 Pt C):E1181-6. doi: 10.1111/j.1464-410X.2012.11519.x. Epub 2012 Oct 4.
    • The role of BRCA1 and BRCA2 in prostate cancer.
    • Castro E, Eeles R.
    • Asian J Androl. 2012 May;14(3):409-14. doi: 10.1038/aja.2011.150. Epub 2012 Apr 23.
    • Update on the IMPACT Study and Implications for Men with BRCA Mutations.
    • Jacquelyn Powers.
    • FORCE. Be Empowered Webinars. 2012 Mar 27.